SCIENTIFIC BOARD

Rakesh Dixit is a prominent expert in antibody-drug conjugates (ADCs) with over three decades of experience in biotech and pharmaceuticals. He currently leads Bionavigen, a consultancy specializing in the development of biologics, cell and gene therapies, and small molecule drugs. Previously, he held senior roles at major companies like Merck, Johnson & Johnson, and AstraZeneca's MedImmune, where he played a key part in bringing several biologics and small-molecule therapies to market. His contributions to ADC research earned him the "Long-Standing Contributor to ADCs" award from the World ADC Forum in 2020

John Lambert is a leading authority in the field of antibody-drug conjugates (ADCs). He spent a significant portion of his career at ImmunoGen, where he served as Chief Scientific Officer from 2008 to 2015. During his tenure, he was instrumental in the development of key ADCs, including Kadcyla® for HER2-positive breast cancer and Elahere® for ovarian cancer. Lambert has authored over 120 scientific papers and remains active as a consultant and advisor in the biotech industry, contributing to the continued advancement of ADC therapies

Bertrand Allard now serves as Chief Scientific Officer (CSO) at Skymab. He has a rich background in pharmacology and immunology, with over eight years of experience in John Stagg's lab in Montreal, where he honed his expertise in tumor immunology. Bertrand has specialized in developing monoclonal antibodies targeting transmembrane receptors and led significant research projects in producing anti-GPCR monoclonal antibodies during his tenure at CEA.
Since joining Skymab in 2020, he has played a crucial role in identifying new potential targets for cancer immunotherapy. Bertrand holds a PhD in immunology from Paris 11 University and an engineering diploma from the Polytechnic School of Nice-Sophia Antipolis.